Jaguar Health Announces Approval of Proposals at Stockholder Meeting

Jaguar Health, Inc. reported that all three proposals presented at its Special Meeting of Stockholders on December 8, 2025, received approval. The specific details of these proposals can be found in the company’s proxy statement filed on November 10, 2025, with the SEC. This document is accessible on the SEC website and Jaguar Health's corporate page.

Importantly, initial results from a proof-of-concept trial indicate that the company’s drug crofelemer could increase the survival of infants with microvillus inclusion disease (MVID) by reducing the necessary volume of parenteral support. Jaguar Health has engaged with the FDA, pursuing expedited approval for this treatment.

The firm’s CEO, Lisa Conte, will present at the Emerging Growth Conference, providing further insights into Jaguar's ongoing developments.